A fifty-two-year-old managing director of a mid-cap manufacturing group on the Ikeja industrial axis collapses on a Tuesday morning in his own boardroom, halfway through the quarterly numbers, in front of seven of his direct reports. The systolic on the cuff at the company clinic, twenty minutes later, is 218. The diastolic is 132. The serum creatinine, when the labs return that evening from his admission to a private hospital in Ikoyi, is 184. The HbA1c is 9.1. The echocardiogram, the following morning, describes a left ventricle with concentric hypertrophy and an ejection fraction at the lower end of normal. None of this is, in any honest reading of his clinical history, a surprise. His last contact with a doctor was nineteen months earlier, at the company-mandated annual physical, where his blood pressure was recorded as 144/92 and described in the typed report as "mildly elevated, advised lifestyle modification." There was no follow-up. He felt completely well. He had felt well for thirty years.
This is the modal presentation of the Lagos and Abuja executive in his second medical event, and frequently in his first. The clinical literature on what produces it is now mature, the tests that catch it are widely available within five kilometres of his office, and the conditions involved are, between them, responsible for almost the entire preventable cardiovascular and metabolic mortality of the executive cohort under sixty. There are seven of them. They are worth naming together, because the corporate-medicine conversation in Nigeria has not yet developed the habit of treating them as a single screening matrix to be run on a single patient on a defined cadence — which is what they are.
What the executive cohort is actually exposed to
The seven conditions in question do not arise in the executive demographic by accident, and they are not the same seven that would dominate a population-level screening conversation in a younger or less professionally pressured cohort. The Lagos manufacturing MD, the Abuja oil-and-gas principal, the Victoria Island partner, and the Lekki fintech founder share a recognisable cardiometabolic phenotype, and the phenotype is produced by a recognisable life. The hours are long. The sleep is short. The alcohol is consistent. The food is rich and frequently late. The standing exposure to sympathetic activation — traffic, deadline cycles, payroll cycles, board cycles — is essentially continuous from age thirty-two onward. The genetic background, in the West African adult, is meaningfully more cardiovascularly vulnerable than the genetic background against which most of the global screening guidelines were originally calibrated.
This is the cohort, in other words, in which the silent conditions are not theoretical. They are statistically certain in some fraction of the patients in the boardroom every Tuesday. The question the screening practice has to answer is not whether they are present. It is which patient has which, at what stage, on what trajectory.
Masked hypertension
The first and most consequential of the seven is hypertension, and within hypertension it is specifically the masked hypertensive phenotype that the Nigerian executive cohort over-represents. The patient's clinic reading on a Tuesday morning is 128/82. His twenty-four-hour ambulatory reading, run with a monitor he wears through a normal working day, is averaging 152/98, with nocturnal non-dipping. He is, on the ambulatory data, a hypertensive patient with end-organ exposure that the in-clinic reading has been failing to document for years. The single-snapshot blood pressure is the lowest-resolution information the screening physician can act on. The forty-eight-hour ambulatory monitor is the standard of care for the patient with any cardiovascular risk factor and is essentially never ordered in routine Nigerian primary care for the asymptomatic executive. The cost of the monitor in Lagos is in the order of forty thousand naira. The cost of the stroke is in the order of forty million.
The HbA1c trajectory
The second is the trajectory toward Type 2 diabetes, and the operative word is trajectory. The HbA1c is a three-month integrated measure of glycaemic exposure, and the single highest-yield test in the executive screening menu. The patient whose value moves from 5.4 at forty-two to 5.9 at forty-five to 6.3 at forty-eight is on a trajectory that, in essentially every published cohort, terminates at frank diabetes within the following decade unless something interrupts it. The interruption is available — weight, sleep, and exercise will reverse the trajectory in the patient still in the pre-diabetic window — but it is only available to the patient whose physician is reading the trajectory rather than the single value. The HbA1c of 5.9, returned alongside a casual report describing it as "within normal limits," is the most under-acted-on result in Nigerian executive medicine. It is also the result that, identified and acted on in the year it appears, distinguishes the patient who will spend his fifties on metformin from the patient who will not.
Obstructive sleep apnea
The third is obstructive sleep apnea, and the under-diagnosis here is severe. The Nigerian executive cohort, particularly the male executive over forty with central adiposity and a collar size above forty-three centimetres, carries a prevalence of moderate-to-severe OSA that the published audit data places somewhere between twenty and thirty per cent. Almost none of these patients have been formally tested. The clinical pattern — daytime fatigue, post-lunch microsleeps, witnessed snoring with apnoeic pauses, blood pressure that responds poorly to standard antihypertensives, atrial arrhythmias appearing in the fifth decade — is recognisable but is consistently attributed to the executive lifestyle and not to the underlying respiratory diagnosis. A home sleep study, now available in Lagos and Abuja for under one hundred thousand naira, is the screening tool. The CPAP, when needed, is one of the highest-impact single therapies in cardiometabolic medicine — and is essentially the only intervention that reliably lowers the cardiovascular and arrhythmic risk associated with severe untreated OSA.
The creatinine creep
The fourth is chronic kidney disease, and what the practice sees most often is not the patient who knows he has CKD. It is the patient whose serum creatinine has moved silently from 84 at forty-five to 102 at forty-eight to 124 at fifty-one, with each annual value reported as "within normal limits" because each value, in isolation, sits just inside the upper reference. The estimated glomerular filtration rate corresponding to that trajectory has moved from a comfortable 102 to a borderline 76 to a clinically actionable 58. The patient has lost forty per cent of his renal function across six years without anyone reading the trend. The reasons are familiar — hypertensive nephrosclerosis, the cumulative effect of poorly-controlled glycaemia, the contribution of unregulated NSAID use for the chronic musculoskeletal complaints of the over-fifty executive — and they are all modifiable when identified at 102 and unmodifiable when identified at 240. The creatinine trajectory is the second most under-read trajectory in Nigerian executive medicine after the HbA1c.
Lipoprotein(a)
The fifth is Lipoprotein(a), and the issue here is essentially an ordering problem. Lipoprotein(a) is a genetically determined, lifetime-stable, independently atherogenic lipoprotein particle. It is elevated in approximately twenty per cent of the population. It conveys a cardiovascular risk that is independent of LDL cholesterol, independent of statin therapy, and not captured anywhere in the standard lipid panel as it is run in the average Nigerian private hospital. It is measured once in a lifetime, costs around twenty-five thousand naira in Lagos, and is essentially never ordered. The patient with a standard lipid panel reported as "within target on atorvastatin 20 mg" and a Lipoprotein(a) of 92 nmol/L is a patient whose cardiovascular trajectory is not being managed. He is being managed against the wrong number. The single test, run once, defines whether he is in the cohort that will benefit from aggressive LDL-lowering and emerging Lipoprotein(a)-directed therapies or the cohort that will not.
Sub-clinical coronary atherosclerosis
The sixth is sub-clinical atherosclerosis, and the operative test is the coronary artery calcium score. The CAC score is a non-contrast computed tomography measurement of the calcium burden in the coronary arteries, returns a numeric value that maps onto a stratified cardiovascular risk over the following decade, costs in the order of eighty thousand naira in Lagos and Abuja, and is — in any patient over forty with two or more conventional risk factors — the most prognostically powerful single test available in cardiovascular medicine. A CAC score of zero in a fifty-year-old executive with hypertension and dyslipidaemia is a different patient, on a different trajectory, than the same patient with a CAC of 280. The first is, against the standard tables, at low ten-year cardiovascular risk and may not need pharmacological intervention. The second is at high risk and needs aggressive intervention now. The same lipid panel, the same blood pressure, the same family history would have produced the same conventional risk score for both. The CAC distinguishes them. It is essentially never ordered in routine Nigerian executive primary care.
Non-alcoholic fatty liver disease
The seventh is non-alcoholic fatty liver disease, which in the Nigerian executive demographic frequently overlaps with the alcohol the patient is also consuming, producing a hybrid liver pathology that the non-alcoholic in the name does not quite capture. The published prevalence of fatty liver in Nigerian adults sits between fifteen and thirty per cent in the most recent cohort data, and is meaningfully higher in the executive sub-cohort. The screening tools are cheap and underused: a liver ultrasound, an ALT trajectory rather than an ALT snapshot, a FIB-4 score calculated from age, ALT, AST, and platelet count from the routine annual panel. The ALT that has moved from 28 to 41 to 58 to 72 across four annual physicals is a liver telling the practice exactly what is happening to it, and the executive whose annual report has marked it as "within normal limits" each time is a patient whose hepatic fibrosis has been quietly progressing under cover of a satisfactory paragraph.
The cadence the executive cohort actually needs
The conversation about executive screening in Nigeria has not yet developed the habit of presenting these seven conditions as a single matrix on a defined cadence, which is the only form in which they are actually useful. The matrix is not exotic. A baseline run at age forty, or at the year the patient enters significant executive responsibility, includes a full lipid panel with Lipoprotein(a) measured once, an HbA1c, a fasting insulin and HOMA-IR, a serum creatinine with eGFR, a urinalysis with albumin-to-creatinine ratio, an ambulatory blood pressure trace, a liver ultrasound with ALT and FIB-4, an Epworth Sleepiness Scale with a low threshold for a home sleep study, and — in the patient over forty with any risk factor — a coronary artery calcium score. The annual cadence repeats the HbA1c, the lipid panel without Lipoprotein(a), the creatinine, the liver enzymes, and the ambulatory blood pressure. The CAC score and the sleep study repeat at the intervals their initial results dictate.
The matrix runs in a morning. It costs, at the upper bound, in the order of three hundred thousand naira at the annual cadence. It catches every one of the seven conditions in the asymptomatic window in which they are reversible or aggressively modifiable. It is the most cost-effective single intervention in the medical care of the Nigerian executive class — and is, in routine corporate primary care, almost never ordered as a single coherent panel. The patient gets the cheaper, lower-resolution version, with the higher-yield tests omitted on the assumption that the patient feels well and therefore does not need them. The assumption is the problem. The patient does feel well. He felt well in the boardroom, three minutes before the systolic crossed 218, and he had felt well for thirty years. Feeling well is the condition the screening matrix exists for, not the reason to dispense with it.
The honest close
The clinical pattern at the top of this piece resolved, in this particular patient, well. The MD spent six days in the cardiology unit. He is now on an ACE inhibitor, a calcium-channel blocker, a statin titrated to an LDL of 1.6, metformin at the higher dose, and a CPAP machine that the home sleep study, run on the fifth day of his admission, indicated he had needed for at least seven years. He is back in his boardroom on a Tuesday morning, three months later, running quarterly numbers with a blood pressure of 128/78 and an HbA1c that has moved from 9.1 to 7.4 to a projected target below 6.5 by year's end. The structural damage to his left ventricle and his kidneys is not entirely reversible. The trajectory, from this point forward, is.
The clinical work that was actually heroic in this case was the work that did not happen — the eight or nine years in which the seven conditions were present, identifiable, and acting on him, and during which the routine screening relationship caught none of them. The serious version of executive medicine in Nigeria is not the cardiology unit that successfully managed the event. It is the practice that, at year minus seven, was already reading his HbA1c trajectory, already running his ambulatory blood pressure, already measuring his Lipoprotein(a), already calculating his FIB-4, already booking his CAC, and already explaining to him that the absence of symptoms was the diagnosis the screening matrix was built to find.
The seven conditions are not exotic. The tests are not exotic. The cadence is not exotic. The discipline of running them as a single panel on the asymptomatic executive, year after year, against a trajectory rather than a threshold, is the only part of the picture that is not already in place — and it is the only part that determines whether the boardroom on a Tuesday morning is the place a number is presented or the place a cardiovascular event is.